Tag Archives: survival benefit

Multivitamins Don't Raise Colon Cancer Survival, Prevent Recurrence

Taking a daily multivitamin didn’t improve survival or reduce the risk that colon cancer would come back for stage III patients enrolled in a clinical trial of chemotherapy after surgery. Although about half of patients in the trial took a multivitamin supplement during their treatment, the vitamin didn’t improve their outcomes, nor did it reduce side effects.  At the same time, multivitamin use didn’t have a detrimental effect.

Continuing Avastin after Colorectal Cancer Gets Worse Increases Survival Time

Colorectal cancer patients benefited when they continued to include Avastin® (bevacizumab) in their chemotherapy plan after their cancer got worse after initial treatment. They lived longer after beginning a second round of chemotherapy with Avastin than did other patients who got chemo without Avastin or those who didn’t get any chemotherapy at all. The results are based on the ARIES study which observed patients after cancer progressed after either first or second line chemotherapy with Avastin.  The analysis will be presented at the American Society of Clinical Oncology in June.

Colon Cancer Patients with Close Family History Do Better

Colon cancer patients with a first-degree relative who also had colon cancer have a significantly better prognosis. In a recent study, even after all risk factors were taken into consideration, they had less chance of cancer recurring and less chance of dying than people without a close family history. However, the same thing was not true for rectal cancer.

KRAS Made No Difference in Stage III Outcome

Patients with stage III colon cancer didn’t do better or worse if their tumor had mutated KRAS. Studying KRAS in the tumors of about half the patients in a large clinical trial of chemotherapy for stage III colon cancer, researchers found no differences in disease-free, recurrence-free, or overall survival.  This remained true no matter which chemotherapy the patients received.

PACCE Results: Poorer Outcomes When Panitumumab is Added to Chemotherapy and Avastin

Patients being treated for the first time with chemotherapy and Avastin® (bevacizumab) do worse if Vectibix™ (panitumumab) is added to their chemotherapy.  Median time until the cancer progresses is shorter, and they have more serious side effects. KRAS status made no difference.  Both patients with wild-type and mutated KRAS in their tumors had worse outcomes when panitumumab was part of their treatment. The research team recommends that Vectibix not be added to chemotherapy with Avastin to treat colorectal cancer that has spread.

Surgery at NCI Centers Shows Better Survival

Patients who had surgery for colon or rectal cancer performed at a National Cancer Institute Designated Center had less risk of death immediately after surgery and better long-term survival. Looking at nearly 34,000 people who had surgery for colon cancer and 8,600 who had rectal cancer surgery, researchers found a 26 percent increase in long term survival when the operation was done in an NCI-designated cancer center. Having surgery in an NCI-designated center cut the risk of dying in the hospital or within 30 days after surgery in half for colon cancer patients.  Post surgery deaths were 6.7 percent in non-NCI centers and 3.2 percent in NCI-designated centers.  There was

KRAS Status Doesn't Impact Treatment with 5-FU Alone

While researchers have found that colorectal cancer tumors that have mutated KRAS genes don’t respond to treatment with EFGR inhibitors Erbitux®(cetuximab) and Vectibix™(panitumumab), is the same thing true for other drugs? 5-FU (fluorouracil) is the backbone of most colorectal cancer treatment, given alone or in combination with other drugs.  What does KRAS status mean when 5-FU is the only treatment?

KRAS Mutation Status Predicts Response to Erbitux in Canadian Study

Another study has shown that colon or rectal cancer patients whose tumors have mutated KRAS don’t benefit from Erbitux® (cetuximab).  However, in the study when only patients with normal or wild-type KRAS were considered, survival time almost doubled after treatment with Erbitux began.